Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

BCC is new territory for cancer immunotherapies however, and Libtayo is the first drug in the PD-1/PD-L1 inhibitor class to get go-ahead in this common form of skin cancer. It's been cleared for ...

There's no shortage of cancer immunotherapies trying to knock ... Sanofi and Regeneron have reported new data for Libtayo that suggests the drug could be a contender. Overall survival (OS) was ...

Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will recover. That isn't the case for many companies that have lagged broader ...

Risk factors for secondary skin cancer after blood or marrow transplant include those who had treatment with a monoclonal ...

THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who progressed on two or more ...

A novel AI model was able to achieve 99.86% accuracy for diagnosing skin conditions, even in people with darker skin tones or ...

University of Queensland researchers have discovered immunotherapy, when used to treat people with advanced cancers, also ...

A new pilot cohort study linked immune checkpoint inhibitors with a reduction in actinic keratoses in patients undergoing ...